ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Springworks Therapeutics, Inc. ?
1
The company has declared Positive results for the last 5 consecutive quarters
- NET SALES(Q) At USD 49.09 has Grown at 133.68%
- OPERATING CASH FLOW(Y) Highest at USD -165.43 MM
- NET PROFIT(HY) Higher at USD -155.58 MM
2
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 26.08%, its profits have risen by 26.6%
3
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Market Beating Performance
- The stock has generated a return of 26.08% in the last 1 year, much higher than market (S&P 500) returns of 12.69%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Springworks Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Springworks Therapeutics, Inc. for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Springworks Therapeutics, Inc.
26.08%
0.28
63.61%
S&P 500
13.22%
0.62
20.57%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
194.27%
EBIT Growth (5y)
-216.62%
EBIT to Interest (avg)
-271.98
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.69
Sales to Capital Employed (avg)
0.23
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.45
EV to EBIT
-12.24
EV to EBITDA
-12.42
EV to Capital Employed
24.69
EV to Sales
14.75
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-201.75%
ROE (Latest)
-59.66%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bullish
No Signal
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Bearish
Bearish
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend21What is working for the Company
NET SALES(Q)
At USD 49.09 MM has Grown at 133.68%
OPERATING CASH FLOW(Y)
Highest at USD -165.43 MM
NET PROFIT(HY)
Higher at USD -155.58 MM
ROCE(HY)
Highest at -51.57%
RAW MATERIAL COST(Y)
Fallen by 0.27% (YoY
INVENTORY TURNOVER RATIO(HY)
Highest at 2.12%
-4What is not working for the Company
CASH AND EQV(HY)
Lowest at USD 595.86 MM
DEBT-EQUITY RATIO
(HY)
Highest at -67.2 %
Here's what is working for Springworks Therapeutics, Inc.
Net Sales
At USD 49.09 MM has Grown at 133.68%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Net Profit
Higher at USD -155.58 MM
than preceding 12 month period ended Mar 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Operating Cash Flow
Highest at USD -165.43 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Inventory Turnover Ratio
Highest at 2.12%
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Raw Material Cost
Fallen by 0.27% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at USD 1.1 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for Springworks Therapeutics, Inc.
Cash and Eqv
Lowest at USD 595.86 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at -67.2 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
